These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 23055389

  • 1. Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
    Lyseng-Williamson KA.
    Mol Diagn Ther; 2012 Oct; 16(5):317-22. PubMed ID: 23055389
    [Abstract] [Full Text] [Related]

  • 2. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 3. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 4. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 20; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 5. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.
    World J Gastroenterol; 2014 Apr 21; 20(15):4208-19. PubMed ID: 24764659
    [Abstract] [Full Text] [Related]

  • 6. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
    Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G.
    Ann Oncol; 2014 Sep 21; 25(9):1756-1761. PubMed ID: 24942275
    [Abstract] [Full Text] [Related]

  • 7. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY.
    Genet Mol Res; 2011 Oct 03; 10(4):3002-12. PubMed ID: 21968808
    [Abstract] [Full Text] [Related]

  • 8. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.
    N Engl J Med; 2009 Apr 02; 360(14):1408-17. PubMed ID: 19339720
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.
    J Clin Oncol; 2010 Nov 01; 28(31):4706-13. PubMed ID: 20921462
    [Abstract] [Full Text] [Related]

  • 10. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
    Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.
    World J Gastroenterol; 2010 Jul 07; 16(25):3133-43. PubMed ID: 20593498
    [Abstract] [Full Text] [Related]

  • 11. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW.
    Invest New Drugs; 2012 Aug 07; 30(4):1607-13. PubMed ID: 21706149
    [Abstract] [Full Text] [Related]

  • 12. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A.
    Clin Colorectal Cancer; 2015 Sep 07; 14(3):162-9. PubMed ID: 25861836
    [Abstract] [Full Text] [Related]

  • 13. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V.
    Ann Oncol; 2012 Jul 07; 23(7):1693-9. PubMed ID: 22219013
    [Abstract] [Full Text] [Related]

  • 14. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F.
    J Clin Oncol; 2015 Mar 01; 33(7):692-700. PubMed ID: 25605843
    [Abstract] [Full Text] [Related]

  • 15. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
    Chen Y, Cao D, Bi F, Li Q, Qiu M.
    Med Oncol; 2014 May 01; 31(5):935. PubMed ID: 24683007
    [Abstract] [Full Text] [Related]

  • 16. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.
    Oncology; 2010 May 01; 79(5-6):415-22. PubMed ID: 21474966
    [Abstract] [Full Text] [Related]

  • 17. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY.
    Clin Cancer Res; 2009 Jul 01; 15(13):4508-13. PubMed ID: 19549774
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct 01; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 19. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, Jakobsen A.
    Ann Oncol; 2009 May 01; 20(5):879-84. PubMed ID: 19179548
    [Abstract] [Full Text] [Related]

  • 20. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
    Láng I, Köhne CH, Folprecht G, Rougier P, Curran D, Hitre E, Sartorius U, Griebsch I, Van Cutsem E.
    Eur J Cancer; 2013 Jan 01; 49(2):439-48. PubMed ID: 23116683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.